Table 1.
Baseline characteristics
| Baseline characteristics | |
|---|---|
| Age (years) | 66.8 ± 8.5 |
| ≥75 years | 52 (18.6%) |
| AF duration (years) | 1.8 [0.5–5.5] |
| Paroxysmal AF | 147 (52.5%) |
| Female | 97 (34.6%) |
| Previous heart failure hospitalization | 152 (54.3%) |
| NYHA class | 1.8 [0.5–5.5] |
| ≥II | 60 (21.4%) |
| Hypertension | 185 (66.1%) |
| Diabetes | 61 (21.8%) |
| Ischaemic stroke | 30 (10.7%) |
| CHADS2 score | 1.6 ± 1.1 |
| CHA2DS2‐VASc score | 2.7 ± 1.5 |
| ≥2 | 216 (77.1%) |
| Echocardiography data | |
| Left ventricular diastolic dimension (mm) | 58.0 ± 8.1 |
| ≥55 mm | 41 (14.6%) |
| Left ventricular ejection fraction (%) | 53.3 ± 17.7 |
| 40–49% | 28 (10.0%) |
| <40% | 85 (30.4%) |
| Left atrial diameter (mm) | 44.3 ± 6.5 |
| ≥40 mm | 221 (78.9%) |
| E/e′ | 13.4 ± 6.2 |
| ≥15 | 51 (30.0%) |
| Moderate‐to‐severe mitral regurgitation | 54 (19.3%) |
| Laboratory data | |
| Cre (mg/dL) | 0.9 (0.8–1.1) |
| eGFR (mL/min/1.73 m2) | 57.4 ± 20.3 |
| BNP (pg/dL) | 232 (132–349) |
| ≥200 pg/dL | 177 (64.1%) |
| Medications at discharge | |
| Oral anticoagulant | 280 (100%) |
| Antiplatelet | 81 (28.9%) |
| Statin | 73 (26.1%) |
| ACE‐I/ARB | 141 (50.4%) |
| Beta‐blockers | 143 (51.1%) |
| Verapamil/diltiazem | 44 (15.7%) |
| Other Ca channel blockers | 52 (18.6%) |
| Digitalis | 46 (16.4%) |
| Furosemide | 50 (17.9%) |
| Mineralocorticoid receptor antagonist | 46 (16.4%) |
ACE‐I, angiotensin‐converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BNP, B‐type natriuretic peptide; Ca, calcium; eGFR, estimated glomerular filtration rate; NYHA, New York Heart Association.
Categorical variables are presented as number (percentage). Continuous variables are presented as mean ± standard deviation or median and inter‐quartile range.